For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Acadia Pharmaceuticals Inc.

USPTO Granted Patents = 93

CIPO Patents = 24

EPO Patents = 16

Trademarks = 30

Forward Citations = 1,317

Loading Chart...

Loading Chart...

116 inventors (with patents filed for the assignee):

Carl-Magnus A Andersson (25 out of 26 patents)

Mark R Brann (24 out of 25 patents)

Roger Olsson (19 out of 20 patents)

4. Allan K Uldam (19 out of 19 patents)

5. David M Weiner (18 out of 20 patents)

6. Robert E Davis (17 out of 144 patents)

7. Bo-Ragnar Tolf (16 out of 16 patents)

8. Nathalie Schlienger (15 out of 15 patents)

9. Kristian Norup Koch (11 out of 11 patents)

10. Niels Skjaerbaek (9 out of 9 patents)

11. Mikkel Boas Thygesen (7 out of 7 patents)

12. Ethan S Burstein (6 out of 6 patents)

13. Marlon Carlos (6 out of 23 patents)

14. Magnus Gustafsson (6 out of 7 patents)

15. Eva Louise Hansen (6 out of 7 patents)

Core Competencies:

Pimavanserin

Neurodegenerative Diseases

Selective Serotonin Receptor Inverse Agonists

Muscarinic Agonists

Pain Treatment Compounds

Alzheimer's Disease Psychosis

Carbetocin Drug Products

Thiazoline Anti-Hyperalgesic Agents

Tetrahydroquinoline Analogues

Estrogen Receptor Modulators

Norketamine Compounds

Agitation Treatment Processes

93 patents: Sort by Forward Citations

1. 12492167 - Crystalline forms of trofinetide (2025-12-09),

2. 12466783 - Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods (2025-11-11),

3. 12139477 - Compounds, salts thereof and methods for treatment of diseases (2024-11-12),

4. 11844764 - Agitation process for preparing a carbetocin drug product (2023-12-19),

5. 11840515 - Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c (2023-12-12),

6. 11827600 - Crystalline forms of trofinetide (2023-11-28),

7. 11464768 - Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis (2022-10-11),

8. 11452721 - Formulations of pimavanserin (2022-09-27),

9. 11440884 - Compounds, salts thereof and methods for treatment of diseases (2022-09-13),

10. 11345693 - Compounds, salts thereof and methods for treatment of diseases (2022-05-31),

11. 11191757 - Combination of pimavanserin and cytochrome P450 modulators (2021-12-07),

12. 11161826 - Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent (2021-11-02),

13. 11135211 - Pimavanserin for treating impulse control disorder (2021-10-05),

14. 11091473 - Compounds for pain treatment, compositions comprising same, and methods of using same (2021-08-17),

15. 10981871 - Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C (2021-04-20),

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. With a strong emphasis on neuroscience, ACADIA is committed to improving the lives of patients suffering from neurological and related psychiatric disorders.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

93 Patents

#67 in San Diego, CA

#926 in California

#3,881 in US

#8,032 in the World

San Diego, CA, United States of America

Acadia Pharmaceuticals Inc.

Forward Citations = 1,317

116 inventors:

Carl-Magnus A Andersson (25 out of 26 patents)

Mark R Brann (24 out of 25 patents)

Roger Olsson (19 out of 20 patents)

4. Allan K Uldam (19 out of 19 patents)

5. David M Weiner (18 out of 20 patents)

Please report any incorrect information to support@idiyas.com

Loading…